H. Lundbeck, Lundbeck and Forest announce federal court upholds Lexapro® patent

H. Lundbeck A/S and Forest Laboratories, Inc. said today that the U.S. District Court for the District of Delaware has determined that the U.S. patent covering escitalopram, the active ingredient in Lexapro®, is both valid, enforceable and infringed by Ivax/Teva's proposed generic product, thereby confirming Lundbeck’s and Forest’s patent rights for Lexapro®, which expire in March 2012.